{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:28:38Z","timestamp":1747153718429,"version":"3.40.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00520-020-05958-0","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T18:03:05Z","timestamp":1609696985000},"page":"3951-3959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intergenerational comparison of 5-HT3RA in the prevention of chemotherapy-induced nausea and vomiting in gastric cancer patients receiving cisplatin-based chemotherapy: an observational study using a Japanese administrative claims database"],"prefix":"10.1007","volume":"29","author":[{"given":"Yuji","family":"Kunitomi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotsugu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Ide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-4071","authenticated-orcid":false,"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"key":"5958_CR1","doi-asserted-by":"crossref","unstructured":"Morita S, Kobayashi K, Eguchi K, Matsumoto T, Shibuya M, Yamaji Y, Sakamoto J, Ohashi Y (2003) Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model Jpn J Clin Oncol 33: 470\u2013476","DOI":"10.1093\/jjco\/hyg083"},{"key":"5958_CR2","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478","journal-title":"J Clin Oncol"},{"key":"5958_CR3","doi-asserted-by":"crossref","unstructured":"Gilmore J, D\u2019Amato S, Griffith N, Schwartzberg L (2018). Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists. Cancer management and research 10: 1827-1857","DOI":"10.2147\/CMAR.S166912"},{"key":"5958_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103\u2013109","journal-title":"J Clin Oncol"},{"key":"5958_CR5","doi-asserted-by":"crossref","unstructured":"Majem M, Moreno ME, Calvo N, Feliu A, Perez J, Mangues MA, Barnadas A (2011). Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 19: 1983-1990","DOI":"10.1007\/s00520-010-1042-3"},{"key":"5958_CR6","doi-asserted-by":"crossref","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M (2016). 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27: v119-v133","DOI":"10.1093\/annonc\/mdw270"},{"key":"5958_CR7","doi-asserted-by":"crossref","unstructured":"Takeuchi H, Saeki T, Aiba K, Tamura K, Aogi K, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Udagawa Y, Okawa Y, Onozawa Y, Sasaki H, Shima Y, Shimoyama N, Takeda M, Nishidate T, Yamamoto A, Ikeda T, Hirata K (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. International journal of clinical oncology 21: 1-12","DOI":"10.1007\/s10147-015-0852-1"},{"key":"5958_CR8","unstructured":"Network NCC (2020) Anitiemesis (Version .2020 - February 19,2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf."},{"key":"5958_CR9","doi-asserted-by":"crossref","unstructured":"Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, Goto K, Takiguchi T, Ohyanagi F, Kogure Y, Nogami N, Nakao M, Takeda K, Azuma K, Nagase S, Hayashi T, Fujiwara K, Shimada T, Seki N, Yamamoto N (2016). Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 27: 1601-1606","DOI":"10.1093\/annonc\/mdw220"},{"key":"5958_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s005200050161","volume":"6","author":"GR Morrow","year":"1998","unstructured":"Morrow GR, Roscoe JA, Kirshner JJ, Hynes HE, Rosenbluth RJ (1998) Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 6:244\u2013247","journal-title":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"5958_CR11","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer A (2011) Japanese gastric cancer treatment guidelines 2010 (ver. 3) Gastric Cancer 14: 113\u2013123","DOI":"10.1007\/s10120-011-0042-4"},{"key":"5958_CR12","doi-asserted-by":"crossref","unstructured":"Nakashima M, Takeuchi M, Kawakami K (2020) Effectiveness and safety of regorafenib vs. trifluridine\/tipiracil in unresectable colorectal cancer: a retrospective cohort study. Clin Colorectal Cancer","DOI":"10.1016\/j.clcc.2020.05.003"},{"key":"5958_CR13","doi-asserted-by":"crossref","unstructured":"Mizuno K, Takeuchi M, Kanazawa Y, Kitamura M, Ide K, Omori K, Kawakami K (2019) Recurrent laryngeal nerve paralysis after thyroid cancer surgery and intraoperative nerve monitoring. Laryngoscope 129: 1954\u20131960","DOI":"10.1002\/lary.27698"},{"key":"5958_CR14","doi-asserted-by":"crossref","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21: 242-249","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"5958_CR15","doi-asserted-by":"crossref","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25: 1333-1339","DOI":"10.1093\/annonc\/mdu096"},{"key":"5958_CR16","doi-asserted-by":"crossref","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375: 134\u2013142","DOI":"10.1056\/NEJMoa1515725"},{"key":"5958_CR17","doi-asserted-by":"crossref","unstructured":"Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE J Clin Oncol 29: 1495-1501","DOI":"10.1200\/JCO.2010.31.7859"},{"key":"5958_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","volume":"27","author":"H Yamana","year":"2017","unstructured":"Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H (2017) Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol 27:476\u2013482","journal-title":"J Epidemiol"},{"key":"5958_CR19","doi-asserted-by":"crossref","unstructured":"Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, Miyata Y, Takiuchi H, Yamaguchi K, Sasaki Y, Nishina T, Satoh A, Baba E, Tamura T, Abe T, Hatake K, Ohtsu A (2012) Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study Gastric Cancer 15: 313-322","DOI":"10.1007\/s10120-011-0118-1"},{"key":"5958_CR20","doi-asserted-by":"crossref","unstructured":"Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer Oncol Rep 15: 65-71","DOI":"10.3892\/or.15.1.65"},{"key":"5958_CR21","doi-asserted-by":"crossref","unstructured":"Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, Yoshikawa T, Ochiai A, Morita S, Sano T, Kodera Y, Kakeji Y, Sakamoto J, Saji S, Yoshida K (2016) Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101) Gastric Cancer 19: 839-851","DOI":"10.1007\/s10120-015-0518-8"},{"key":"5958_CR22","doi-asserted-by":"crossref","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376: 687-697","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"5958_CR23","doi-asserted-by":"crossref","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9: 215-221","DOI":"10.1016\/S1470-2045(08)70035-4"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05958-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05958-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05958-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T06:20:04Z","timestamp":1622182804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05958-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5958"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05958-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y. K is an company employee of Taiho Pharmaceutical Co., Ltd., Japan. K. K received advisory fees from Shin Nippon Biomedical Laboratories, Ltd., Japan, JMDC Inc., Japan, and LEBER Inc., Japan; holds stocks of Real World Data, Co., Ltd., Japan; and research funds from Sumitomo Dainippon Pharma Co., Ltd., Japan, Pfizer Inc., Japan, Stella Pharma Corporation., Japan, Cmic Co., Ltd., Japan, Suntory Beverage & Food Limited, Japan, Medical Platform Co., Ltd., Japan, Eisai Co., Ltd., Japan, Kyowa Hakko Kirin Co., Ltd., Japan, Mitsubishi Corporation, Japan, and Real World Data, Co, Ltd., Japan. The other authors have no direct or indirect conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Graduate School and Faculty of Medicine, Kyoto University (approval number: R1893, February 20, 2019). The study was performed according to the Ethical Guidelines for Medical and Health Research Involving Human Subjects by the Ministry of Health, Labor, and Welfare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The need for informed consent was exempted because anonymized data were used.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provided consent to publish this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}